Fam162a-flox Mouse

Fam162a, with its specific function yet to be fully elucidated, has been associated with several biological processes. It has been linked to hypoxia-related pathways, glycolysis-related processes, and may play a role in apoptosis regulation. Its involvement in these pathways indicates its importance in maintaining cellular homeostasis and response to various stressors [2,3,4,5,6,7,8,9].

In the context of disease, in patients with inflammatory bowel disease (IBD), Fam162a was identified as one of the 10 marker genes potentially contributing to intestinal barrier repairing, with its expression specific to absorptive cell types in intestinal epithelium [1]. In coronary artery disease (CAD), it was among 4 hub signature genes identified as hypoxia-related genes, and was found to be highly expressed in endothelial cells [2]. In osteosarcoma, a gene signature including Fam162a was constructed related to hypoxia and lactate metabolism, with high-risk scores (where Fam162a was part of the signature) associated with poor prognosis and "cold" tumor characteristics [3]. In IDH-mutant glioma, a hypoxia-related survival score containing Fam162a was identified, which could predict survival independent of other prognostic factors [4]. In colon cancer, Fam162a was part of a 13-gene glycolysis-related prognostic prediction model [5]. In a study on the mechanism of neuronal apoptosis in chronic cerebral ischemia, Foxh1 was shown to transcriptionally promote the expression of Fam162a [6]. In tilapia, differential exon usages of fam162a were detected in response to acute hypoxia treatment in the heart [7]. In mouse neuroblastoma Neuro-2a cells exposed to a mitochondrial toxin, there was a loss of FAM162a mRNA along with changes in mitochondrial-related genes [8]. In osteosarcoma, a risk model based on seven glycolytic genes including Fam162a could effectively evaluate prognosis [9].

In conclusion, Fam162a is implicated in multiple biological processes and disease conditions, especially those related to hypoxia, glycolysis, and tissue repair or tumor prognosis. Studies across different disease models have revealed its potential as a biomarker or therapeutic target in diseases such as IBD, CAD, osteosarcoma, IDH-mutant glioma, and colon cancer. Understanding the function of Fam162a through these disease-based research models provides insights into the underlying molecular mechanisms of these diseases.